Epoetin biosimilar
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Symptomatic Anemia
Conditions
Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas, Myelomas
Trial Timeline
Sep 1, 2009 → Aug 1, 2011
NCT ID
NCT02140736About Epoetin biosimilar
Epoetin biosimilar is a pre-clinical stage product being developed by Pfizer for Chemotherapy-induced Symptomatic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02140736. Target conditions include Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-induced Symptomatic Anemia were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02140736 | Pre-clinical | Completed |
Competing Products
20 competing products in Chemotherapy-induced Symptomatic Anemia